| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30011977 | HIV | ENSG00000069667.16 | protein_coding | RORA | No | No | 6095 | A0A0C4DFP5 A0A0C4DG53 P35398 |
| TVIS30002321 | HIV | ENSG00000069667.16 | protein_coding | RORA | No | No | 6095 | A0A0C4DFP5 A0A0C4DG53 P35398 |
| TVIS30011978 | HIV | ENSG00000069667.16 | protein_coding | RORA | No | No | 6095 | A0A0C4DFP5 A0A0C4DG53 P35398 |
| TVIS30006617 | HIV | ENSG00000069667.16 | protein_coding | RORA | No | No | 6095 | A0A0C4DFP5 A0A0C4DG53 P35398 |
| TVIS30006618 | HIV | ENSG00000069667.16 | protein_coding | RORA | No | No | 6095 | A0A0C4DFP5 A0A0C4DG53 P35398 |
| TVIS30011979 | HIV | ENSG00000069667.16 | protein_coding | RORA | No | No | 6095 | A0A0C4DFP5 A0A0C4DG53 P35398 |
| TVIS30004514 | HIV | ENSG00000069667.16 | protein_coding | RORA | No | No | 6095 | A0A0C4DFP5 A0A0C4DG53 P35398 |
| TVIS30087596 | HIV | ENSG00000069667.16 | protein_coding | RORA | No | No | 6095 | A0A0C4DFP5 A0A0C4DG53 P35398 |
| TVIS30079201 | HIV | ENSG00000069667.16 | protein_coding | RORA | No | No | 6095 | A0A0C4DFP5 A0A0C4DG53 P35398 |
| TVIS30081533 | HIV | ENSG00000069667.16 | protein_coding | RORA | No | No | 6095 | A0A0C4DFP5 A0A0C4DG53 P35398 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | RORA |
|---|---|
| DrugBank ID | DB04540 |
| Drug Name | Cholesterol |
| Target ID | BE0004545 |
| UniProt ID | P35398 |
| Regulation Type | |
| PubMed IDs | 17139284; 17016423; 10592235 |
| Citations | Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. |
| Groups | Approved; Investigational |
| Direct Classification | Cholesterols and derivatives |
| SMILES | [H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCCC(C)C |
| Pathways | Cerivastatin Action Pathway; 3-beta-Hydroxysteroid Dehydrogenase Deficiency; Pamidronate Action Pathway; Ibandronate Action Pathway; Simvastatin Action Pathway; Chondrodysplasia Punctata II, X-Linked Dominant (CDPX2); Smith-Lemli-Opitz Syndrome (SLOS); Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH; Zellweger Syndrome; Lysosomal Acid Lipase Deficiency (Wolman Disease); Steroid Biosynthesis; Hypercholesterolemia; Risedronate Action Pathway; Mevalonic Aciduria; Congenital Bile Acid Synthesis Defect Type II; Apparent Mineralocorticoid Excess Syndrome; Rosuvastatin Action Pathway; Alendronate Action Pathway; Zoledronate Action Pathway; 11-beta-Hydroxylase Deficiency (CYP11B1); Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency; Cholesteryl Ester Storage Disease; Lovastatin Action Pathway; Bile Acid Biosynthesis; Corticosterone Methyl Oxidase I Deficiency (CMO I); 27-Hydroxylase Deficiency; Steroidogenesis; Fluvastatin Action Pathway; Atorvastatin Action Pathway; Pravastatin Action Pathway |
| PharmGKB | |
| ChEMBL | CHEMBL112570 |
